Members in attendance
Al Heaton, RPh, Stuart Williams, J.D., Kathryn Lombardo, M.D., Monica Brands, R.Ph., James Phillips, M.D., Kelly Ruby, Pharm.D., William Korchik, M.D., Margaret Artz, RPh, Ph.D.,

DHS staff present
Sara Drake, RPh., MPH, MBA, Jeff Schiff, M.D., MBA, Dave Hoang, Pharm.D., MBA

Others in attendance
Nina Bandali, Pharm.D., Ariane Casey, Pharm.D.

Report of the Chair
No updates

Approval of the minutes
Minutes from the March and September 2015 meetings were reviewed and approved

New Business

List of Excluded Drugs Review
The committee discussed its responsibility in reviewing and maintaining the list of excluded drugs. The committee recommended to the department by a unanimous vote that there are no changes to be made to the list of excluded drugs.

Specialty Product List Review
The committee discussed adding the following glucagon-like peptide-1 (GLP-1) agonists to the Specialty Product List: Tanzeum (GSK), Trulicity (Lilly), Byetta (AstraZeneca), Bydureon (AstraZeneca), Victoza (Novo Nordisk). The committee recommended to the department by a unanimous vote to add the following drugs to the Specialty Product List: Tanzeum (GSK), Trulicity (Lilly), Byetta (AstraZeneca), Bydureon (AstraZeneca), Victoza (Novo Nordisk)

Class Review:

PCSK9 Inhibitors – Praluent (Sanofi), Repatha (Amgen)
The committee discussed Praluent (Sanofi), Repatha (Amgen). The committee recommended to the department by a unanimous vote that Praluent and Repatha remain on PA. The committee recommended the following criteria: a) intolerance to statin therapy is defined as failure to tolerate at least 2 statins; b) initial approval will be limited to 3 months in duration; c) denial criteria should include Kynamro and Juxtapid

Buprenorphine/naloxone – Suboxone (Indivior), Bunavail (BioDelivery Sciences)
The committee recommended to the department by a unanimous vote that the department manages the category based on cost.
Existing Drugs for Continued PA
The committee discussed Orkambi (Vertex) and recommended to the department by a unanimous vote that Orkambi remains on PA with the additional requirements: a) Patient must be seen at least twice a year by a provider who is on staff at a Cystic Fibrosis (CF) Care Center accredited by the CF Foundation; b) Patient must agree to participate in the CF Patient Registry maintained by the CF Foundation.

The committee discussed Xifaxan for IBS-D
The committee recommended to the department that Xifaxan remain on PA by a unanimous vote with the following additional requirements for IBS-D indication: a) Patient has tried at least two other treatments for IBS-D including over-the-counter antidiarrheal in the past 30 days; b) Documentation of dietary consultation must be provided at time of request

New Drugs for Continued PA
The committee discussed Cholbam (Retrophin). The committee recommended to the department that Cholbam remain on PA by a unanimous vote. The committee recommended additional criteria which includes requiring Cholbam to be prescribed by liver specialist only; initial approval be limited to 4 months in duration; documented evidence of improved liver function required for renewal

The committee discussed Vetassa (Relypssa)
The committee recommended that Vetassa remain on PA by a unanimous vote.

The committee discussed Odomzo (Novartis)
The committee recommended to the department that Odomzo remain on PA by a unanimous vote.

New Specialty Drugs for Continued PA
The committee discussed Aristada (Alkermes) and recommended to the department that Aristada remain on PA by a unanimous vote. The committee recommended the department by a unanimous vote that the department manages the Abilify Maintena and Aritstada based on cost.

The committee discussed Tresiba (Novo Nordisk) and recommended to the department by a unanimous vote that Tresiba remain on PA and Tresiba be placed on the State PDL as non-preferred.

The committee discussed Keveyis (Taro)
The committee recommended to the department by a unanimous vote that Keveyis remain on PA.

Adjournment
The meeting was adjourned at 9:05 pm Central Time.